{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:08:13Z","timestamp":1789762093843,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Egyptian Russian University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Mirabegron and tamsulosin have recently been prescribed to men with overactive bladder for the treatment of benign prostatic hypertrophy. An efficient and environmentally friendly HPLC method was developed to accurately measure the levels of mirabegron and tamsulosin in both their pure form and in medication formulations. Full separation was achieved on an X-Bridge C18 column using a gradient elution of (The A mobile phase was a buffer solution containing 1 mL of trifluoroacetic acid and 3 mL of triethylamine in 1,000 milliliters of water, the pH of the solution was then adjusted to 3 using triethylamine and the B-mobile phase was acetonitrile). The chromatographic peaks were obtained at a wavelength of 220\u00a0nm. Mirabegron and tamsulosin were identified with retention time values of 2.4\u00a0min and 8.9\u00a0min, respectively. In the concentration ranges of 2.5\u201355\u00a0\u00b5g\/mL for mirabegron and 5\u2013110\u00a0\u00b5g\/mL for tamsulosin, remarkable linearity was seen. The limits of detection for the two analytes were 0.28 and 0.55\u00a0\u00b5g\/mL, respectively, and their R<jats:sup>2<\/jats:sup> values were 0.9999. The new HPLC method was evaluated for its environmental friendliness using the Analytical GREEness (AGREE) metric. Furthermore, the suggested technique was considered practicable based on the evaluation conducted using the Blue Applicability Grade Index (BAGI) assessment. Both evaluation methods were quite successful, yielding scores of 0.52 and 80, respectively. Compared to the TLC-reported method, HPLC is the preferred choice for the separation of the two analytes due to its sensitivity.<\/jats:p>","DOI":"10.1038\/s41598-025-89216-5","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T06:57:55Z","timestamp":1740639475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Green HPLC technique development for the simultaneous determination of the potential combination of Mirabegron and Tamsulosin"],"prefix":"10.1038","volume":"15","author":[{"given":"Eman A.","family":"Bahgat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanaa","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam M.","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar M","family":"El-Abassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"89216_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bph.13367","volume":"173","author":"EC Alexandre","year":"2016","unstructured":"Alexandre, E. C. et al. Mirabegron relaxes urethral smooth muscle by a dual mechanism involving \u03b23-adrenoceptor activation and \u03b11\u2010adrenoceptor blockade. Br. J. Pharmacol. 173, 415\u2013428 (2016).","journal-title":"Br. J. Pharmacol."},{"key":"89216_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000447205","volume":"11","author":"E Leron","year":"2018","unstructured":"Leron, E., Weintraub, A. Y., Mastrolia, S. A. & Schwarzman, P. Overactive bladder syndrome: evaluation and management. Curr. Urol. 11, 117\u2013125 (2018).","journal-title":"Curr. Urol."},{"key":"89216_CR3","first-page":"S580","volume":"6","author":"P Abrams","year":"2000","unstructured":"Abrams, P., Kelleher, C. J., Kerr, L. A. & Rogers, R. G. Overactive bladder significantly affects quality of life. Am. J. Manag Care. 6, S580\u2013S590 (2000).","journal-title":"Am. J. Manag Care"},{"key":"89216_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","volume":"87","author":"I Milsom","year":"2001","unstructured":"Milsom, I. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 87, 760\u2013766 (2001).","journal-title":"BJU Int."},{"key":"89216_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart, W. F. et al. Prevalence and burden of overactive bladder in the United States. World J. Urol. 20, 327\u2013336 (2003).","journal-title":"World J. Urol."},{"key":"89216_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2021.10879","volume":"22","author":"I Scarneciu","year":"2021","unstructured":"Scarneciu, I. et al. Overactive bladder: a review and update. Exp. Ther. Med. 22, 1\u20138 (2021).","journal-title":"Exp. Ther. Med."},{"key":"89216_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams, P. et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Eur. Urol. 61, 37\u201349 (2003).","journal-title":"Eur. Urol."},{"key":"89216_CR8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.eururo.2014.12.038","volume":"67","author":"C Gratzke","year":"2015","unstructured":"Gratzke, C. et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur. Urol. 67, 1099\u20131109 (2015).","journal-title":"Eur. Urol."},{"key":"89216_CR9","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1007\/s00345-019-03040-x","volume":"38","author":"E El Helou","year":"2020","unstructured":"El Helou, E. et al. The use of mirabegron in neurogenic bladder: a systematic review. World J. Urol. 38, 2435\u20132442 (2020).","journal-title":"World J. Urol."},{"key":"89216_CR10","doi-asserted-by":"publisher","first-page":"110258","DOI":"10.1016\/j.microc.2024.110258","volume":"200","author":"EA Bahgat","year":"2024","unstructured":"Bahgat, E. A., Saleh, H., Hendawy, H. A. M. & Darwish, I. M. Challenging electroanalytical method for the determination of mirabegron in biological samples and pharmaceutical formulations. Microchem J. 200, 110258 (2024).","journal-title":"Microchem J."},{"key":"89216_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/jssc.202100980","volume":"45","author":"EB Kamel","year":"2022","unstructured":"Kamel, E. B. Two green chromatographic methods for the quantification of tamsulosin and solifenacin along with four of their impurities. J. Sep. Sci. 45, 1305\u20131316 (2022).","journal-title":"J. Sep. Sci."},{"key":"89216_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756287220974130","volume":"12","author":"TW Kang","year":"2020","unstructured":"Kang, T. W. & Chung, H. C. Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy. Ther. Adv. Urol. 12, 1\u20137 (2020).","journal-title":"Ther. Adv. Urol."},{"key":"89216_CR13","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3390\/ph16101457","volume":"16","author":"W Shin","year":"2023","unstructured":"Shin, W., Yang, A. Y., Yoo, H. & Kim, A. Drug\u2013drug interactions between tamsulosin and mirabegron in healthy individuals do not affect pharmacokinetics and hemodynamic parameters significantly. Pharmaceuticals 16, 1457 (2023).","journal-title":"Pharmaceuticals"},{"key":"89216_CR14","doi-asserted-by":"crossref","unstructured":"Mishra, S., Surekha, N. & Chauhan, A. Development and validation of stability indicating RP-HPLC method for simultaneous estimation of silodosin and mirabegron in synthetic mixture. in Ann. Pharm. Fr. 82 243\u2013262 (Elsevier, 2024).","DOI":"10.1016\/j.pharma.2023.12.013"},{"key":"89216_CR15","doi-asserted-by":"publisher","first-page":"115937","DOI":"10.1016\/j.jpba.2023.115937","volume":"240","author":"Y Lou","year":"2024","unstructured":"Lou, Y. et al. Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS\/MS and its application in the clinical determination in patients with tumors associated with overactive bladder. J. Pharm. Biomed. Anal. 240, 115937 (2024).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"89216_CR16","doi-asserted-by":"publisher","unstructured":"Kadam, M. M. M., Singh, R. P. & Charde, M. S. Development and validation of stability indicating UHPLC method for the quantitative estimation of mirabegron and solifenacin succinate in pharmaceutical dosage form. J. Pharm. Negat. Results. 6727\u20136737. https:\/\/doi.org\/10.47750\/pnr.2022.13.S07.815 (2023).","DOI":"10.47750\/pnr.2022.13.S07.815"},{"key":"89216_CR17","first-page":"2652","volume":"20","author":"G Andhale","year":"2022","unstructured":"Andhale, G., Shankarpure, M., Kadam, J., Shelar, M. & Singh, S. RP-HPLC method development and validation for the simultaneous estimation of Mirabegron and Solifenacin succinate in pharmaceutical dosage form. NeuroQuantology 20, 2652 (2022).","journal-title":"NeuroQuantology"},{"key":"89216_CR18","first-page":"36","volume":"1","author":"M Rezaei","year":"2018","unstructured":"Rezaei, M. & Ramazani, A. RP-HPLC method development and validation for the quantitative estimation of mirabegron in extended-release tablets. J. Med. Chem. Sci. 1, 36\u201340 (2018).","journal-title":"J. Med. Chem. Sci."},{"key":"89216_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10337-016-3210-1","volume":"80","author":"AM Yehia","year":"2017","unstructured":"Yehia, A. M., Sami, I., Riad, S. M. & El-Saharty, Y. S. Comparison of two stability-indicating chromatographic methods for the determination of mirabegron in presence of its degradation product. Chromatographia 80, 99\u2013107 (2017).","journal-title":"Chromatographia"},{"key":"89216_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jchromb.2012.01.018","volume":"887","author":"R Van Teijlingen","year":"2012","unstructured":"Van Teijlingen, R. et al. Development and validation of LC\u2013MS\/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study. J. Chromatogr. B. 887, 102\u2013111 (2012).","journal-title":"J. Chromatogr. B"},{"key":"89216_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.17628\/ecb.2019.8.409-415","volume":"8","author":"JN Sangshetti","year":"2019","unstructured":"Sangshetti, J. N., Chivte, D. K., Imran, M. & Mahaparale, P. Development of Hplc method for determination of tamsulosin using quality by design (QBD) approach. Eur. Chem. Bull. 8, 409\u2013414 (2019).","journal-title":"Eur. Chem. Bull."},{"key":"89216_CR22","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2174\/1573412911666151026220542","volume":"12","author":"A Afshari","year":"2016","unstructured":"Afshari, A., Qomi, M. & R. & A novel application of three phase hollow fiber based liquid phase microextraction (HF-LPME) for the HPLC determination of tamsulosin from biological fluids. Curr. Pharm. Anal. 12, 258\u2013265 (2016).","journal-title":"Curr. Pharm. Anal."},{"key":"89216_CR23","doi-asserted-by":"publisher","first-page":"840","DOI":"10.4236\/ajac.2016.711073","volume":"7","author":"HKR Ganthi","year":"2016","unstructured":"Ganthi, H. K. R. et al. Stability indicating HPLC method for quantification of solifenacin succinate & tamsulosin hydrochloride along with its impurities in tablet dosage form. Am. J. Anal. Chem. 7, 840\u2013862 (2016).","journal-title":"Am. J. Anal. Chem."},{"key":"89216_CR24","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1080\/10826076.2013.778637","volume":"37","author":"MK Nasare","year":"2014","unstructured":"Nasare, M. K. et al. Simultaneous determination of finasteride and tamsulosin in combined dosage form by using RP-HPLC method. J. Liq Chromatogr. Relat. Technol. 37, 1176\u20131186 (2014).","journal-title":"J. Liq Chromatogr. Relat. Technol."},{"key":"89216_CR25","unstructured":"Ishaq, B. M., Prakash, K. V. & Mohan, G. K. Simultaneous determination of dutasteride and tamsulosin in pharmaceutical dosage forms by RP-HPLC. in International Conference on Harmonization (ICH) analytical method validation guidelines vol. 15 16 (2014)."},{"key":"89216_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4103\/0976-0105.103817","volume":"3","author":"GS Kumar","year":"2012","unstructured":"Kumar, G. S. & Kumar, B. S. P. Stability-indicating RP-HPLC method for determination of tamsulosin hcl in pharmaceutical dosage form. J. Basic. Clin. Pharm. 3, 255 (2012).","journal-title":"J. Basic. Clin. Pharm."},{"key":"89216_CR27","first-page":"319","volume":"4","author":"SM Mhamunkar","year":"2012","unstructured":"Mhamunkar, S. M., Vyavaharkar, R. Y., Bhoir, S. & I. RP-HPLC method development and validation for the simultaneous estimation of tamsulosin HCl and tolterodine tartrate in pharmaceutical dosage form. Int. J. Pharm. Pharm. Sci. 4, 319\u2013322 (2012).","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"89216_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jchromb.2012.10.012","volume":"909","author":"CI Choi","year":"2012","unstructured":"Choi, C. I. et al. Determination of tamsulosin in human plasma by liquid chromatography\/tandem mass spectrometry and its application to a pharmacokinetic study. J. Chromatogr. B. 909, 65\u201369 (2012).","journal-title":"J. Chromatogr. B"},{"key":"89216_CR29","first-page":"79","volume":"3","author":"MK Thimmaraju","year":"2011","unstructured":"Thimmaraju, M. K., Rao, V. & Gurrala, S. RP HPLC method for the determination of finasteride and tamsulosin in bulk and pharmaceutical formulations. Der Pharm. Lett. 3, 79\u201386 (2011).","journal-title":"Der Pharm. Lett."},{"key":"89216_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4103\/0250-474X.84596","volume":"72","author":"R Kumari","year":"2010","unstructured":"Kumari, R., Dash, P. P., Lal, V. K., Mishra, A. & Murthy, P. N. RP\u2013HPLC method for the estimation of tamsulosin hydrochloride in tablet dosage form. Indian J. Pharm. Sci. 72, 785 (2010).","journal-title":"Indian J. Pharm. Sci."},{"key":"89216_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13065-023-01043-9","volume":"17","author":"MM Abou El-Alamin","year":"2023","unstructured":"Abou El-Alamin, M. M., Toubar, S. S., Mohamed, D. A. & Helmy, M. I. Development of Green HPTLC method for simultaneous determination of a promising combination Tamsulosin and Mirabegron: stability-indicating assay was examined. BMC Chem. 17, 1\u201318 (2023).","journal-title":"BMC Chem."},{"key":"89216_CR32","doi-asserted-by":"publisher","first-page":"108730","DOI":"10.1016\/j.microc.2023.108730","volume":"190","author":"HM El-Sayed","year":"2023","unstructured":"El-Sayed, H. M., Abdellatef, H. E., Hendawy, H. A. M., El-Abassy, O. M. & Ibrahim, H. DoE-enhanced development and validation of eco-friendly RP-HPLC method for analysis of safinamide and its precursor impurity: QbD approach. Microchem J. 190, 108730 (2023).","journal-title":"Microchem J."},{"key":"89216_CR33","doi-asserted-by":"publisher","first-page":"108262","DOI":"10.1016\/j.microc.2022.108262","volume":"185","author":"HM Hafez","year":"2023","unstructured":"Hafez, H. M. et al. Micellar Organic-solvent free HPLC design of experiment for the determination of Ertapenem and meropenem; assessment using GAPI, AGREE and analytical eco-scale models. Microchem J. 185, 108262 (2023).","journal-title":"Microchem J."},{"key":"89216_CR34","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira, F., Wojnowski, W. & Tobiszewski, M. AGREE - Analytical GREEnness metric approach and software. Anal. Chem. 92, 10076\u201310082 (2020).","journal-title":"Anal. Chem."},{"key":"89216_CR35","doi-asserted-by":"publisher","first-page":"7598","DOI":"10.1039\/D3GC02347H","volume":"25","author":"N Manousi","year":"2023","unstructured":"Manousi, N., Wojnowski, W., P\u0142otka-Wasylka, J. & Samanidou, V. Blue applicability grade index (BAGI) and software: a new tool for the evaluation of method practicality. Green. Chem. 25, 7598\u20137604 (2023).","journal-title":"Green. Chem."},{"key":"89216_CR36","volume-title":"Validation of Analytical Procedures: Text and Methodology","author":"ICH Q2 (R2)","year":"2023","unstructured":"ICH Q2 (R2). Validation of Analytical Procedures: Text and Methodology (November, 2023)."},{"key":"89216_CR37","doi-asserted-by":"publisher","first-page":"109755","DOI":"10.1016\/j.microc.2023.109755","volume":"197","author":"G Magdy","year":"2024","unstructured":"Magdy, G., Aboelkassim, E., El-Domany, R. A. & Belal, F. Ultrafast one-pot microwave-assisted green synthesis of silver nanoparticles from Piper longum fruit extract as a sensitive fluorescent nanoprobe for carbamazepine and risperidone in dosage forms and human plasma. Microchem J. 197, 109755 (2024).","journal-title":"Microchem J."},{"key":"89216_CR38","doi-asserted-by":"publisher","first-page":"108829","DOI":"10.1016\/j.microc.2023.108829","volume":"191","author":"HM El-Sayed","year":"2023","unstructured":"El-Sayed, H. M. et al. Safinamide detection based on prussian blue analogue modified solid-contact potentiometric sensor. Microchem J. 191, 108829 (2023).","journal-title":"Microchem J."},{"key":"89216_CR39","doi-asserted-by":"publisher","first-page":"101321","DOI":"10.1016\/j.scp.2023.101321","volume":"36","author":"MA Alossaimi","year":"2023","unstructured":"Alossaimi, M. A., Altamimi, A. S. A., Elmansi, H. & Magdy, G. A green sustainable ultrasensitive micelle-sensitized spectrofluorimetric approach for the estimation of tafamidis in different matrices at picogram levels. Sustain. Chem. Pharm. 36, 101321 (2023).","journal-title":"Sustain. Chem. Pharm."},{"key":"89216_CR40","doi-asserted-by":"publisher","first-page":"123844","DOI":"10.1016\/j.saa.2024.123844","volume":"309","author":"OM El-Abassy","year":"2024","unstructured":"El-Abassy, O. M., Maged, K., El-Henawee, M. M. & Abd El-Hay, S. S. Development of eco-friendly spectrophotometric methods for analysis of metformin hydrochloride and linagliptin in presence of metformin toxic impurity in their pure and dosage forms: validation, practicality and greenness studies. Spectrochim Acta Part. Mol. Biomol. Spectrosc. 309, 123844 (2024).","journal-title":"Spectrochim Acta Part. Mol. Biomol. Spectrosc."},{"key":"89216_CR41","doi-asserted-by":"publisher","unstructured":"Halim, M. K., Badran, O. M. & Abbas, A. E. F. Sustainable chemometric methods boosted by latin hypercube technique for quantifying the recently FDA-approved combination of bupivacaine and meloxicam in the presence of bupivacaine carcinogenic impurity: Comprehensive greenness, blueness, and whiteness. Microchem J. 110276 https:\/\/doi.org\/10.1016\/j.microc.2024.110276 (2024).","DOI":"10.1016\/j.microc.2024.110276"},{"key":"89216_CR42","doi-asserted-by":"publisher","first-page":"464674","DOI":"10.1016\/j.chroma.2024.464674","volume":"1717","author":"M Ntorkou","year":"2024","unstructured":"Ntorkou, M., Kabir, A., Furton, K. G., Tzanavaras, P. D. & Zacharis, C. K. Sol-gel Carbowax 20\u00a0M-zwitterionic ionic liquid composite sorbent-based capsule phase microextraction device combined with HPLC\/post-column derivatization for the determination of lanreotide, a human somatostatin analogue in urine. J. Chromatogr. A. 1717, 464674 (2024).","journal-title":"J. Chromatogr. A"}],"updated-by":[{"DOI":"10.1038\/s41598-025-98289-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89216-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89216-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89216-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T13:57:08Z","timestamp":1745503028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89216-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89216"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89216-5","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-025-98289-1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"11 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-025-98289-1","URL":"https:\/\/doi.org\/10.1038\/s41598-025-98289-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7005"}}